Subcellular localization of the camptothecin analogues, topotecan and gimatecan

Anna Cleta Croce, Giovanni Bottiroli, Rosanna Supino, Enrica Favini, Valentina Zuco, Franco Zunino

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Lipophilicity of camptothecins derivatives has been reported to improve the stability of the lactone ring and to favor rapid uptake and intracellular accumulation. Recently, a novel series of lipophilic camptothecins substituted at position 7 was developed, and gimatecan (ST1481) was selected for clinical development on the basis of some favorable features, including potent cytotoxicity and the unique feature of the lack of recognition by breast cancer resistance-associated protein (BCRP). In this work the intrinsic fluorescence properties of this compound were exploited to investigate its intracellular disposition in comparison with the water-soluble camptothecin, topotecan (TPT), in HT-29 colon carcinoma cells and in a subline, HT-29/Mit, selected for resistance to mitoxantrone and overexpressing BCRP. The study was performed at single-cell level by means of microspectrofluorometry and fluorescence image analysis. The results indicated a quite different subcellular localization of TPT ST1481, since TPT localized mainly in mitochondria, whereas gimatecan exhibited a lysosomal localization. An increased persistence of DNA damage in gimatecan-treated cells was consistent with the interpretation that lysosomes represent a store of active drug. In contrast to gimatecan, which showed a similar localization in HT-29 cells and in the mitoxantrone-resistant subline, the cellular pharmacokinetic of TPT was markedly influenced by overexpression of BCRP protein in the resistant subline. In conclusion, the present results indicating a quite different behavior of the two camptothecins suggest that, apart from intracellular accumulation, subcellular distribution plays a role in their cytotoxic potency and contributes to their pharmacological features.

Original languageEnglish
Pages (from-to)1035-1045
Number of pages11
JournalBiochemical Pharmacology
Volume67
Issue number6
DOIs
Publication statusPublished - Mar 15 2004

Fingerprint

Topotecan
Camptothecin
Mitoxantrone
Breast Neoplasms
Proteins
Fluorescence
Cells
HT29 Cells
Mitochondria
Pharmacokinetics
Lactones
Cytotoxicity
Lysosomes
Image analysis
DNA Damage
ST 1481
Colon
Pharmacology
Derivatives
Carcinoma

Keywords

  • A.u.
  • Arbitrary units
  • BCRP
  • Breast cancer resistance-associate protein
  • Camptothecins
  • Colon carcinoma cells
  • F.I.
  • Fluorescence intensity
  • Resistance
  • Subcellular localization
  • Topotecan
  • TPT

ASJC Scopus subject areas

  • Pharmacology

Cite this

Croce, A. C., Bottiroli, G., Supino, R., Favini, E., Zuco, V., & Zunino, F. (2004). Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochemical Pharmacology, 67(6), 1035-1045. https://doi.org/10.1016/j.bcp.2003.10.034

Subcellular localization of the camptothecin analogues, topotecan and gimatecan. / Croce, Anna Cleta; Bottiroli, Giovanni; Supino, Rosanna; Favini, Enrica; Zuco, Valentina; Zunino, Franco.

In: Biochemical Pharmacology, Vol. 67, No. 6, 15.03.2004, p. 1035-1045.

Research output: Contribution to journalArticle

Croce, AC, Bottiroli, G, Supino, R, Favini, E, Zuco, V & Zunino, F 2004, 'Subcellular localization of the camptothecin analogues, topotecan and gimatecan', Biochemical Pharmacology, vol. 67, no. 6, pp. 1035-1045. https://doi.org/10.1016/j.bcp.2003.10.034
Croce, Anna Cleta ; Bottiroli, Giovanni ; Supino, Rosanna ; Favini, Enrica ; Zuco, Valentina ; Zunino, Franco. / Subcellular localization of the camptothecin analogues, topotecan and gimatecan. In: Biochemical Pharmacology. 2004 ; Vol. 67, No. 6. pp. 1035-1045.
@article{52f36a4a8cae4e25acc1fb6df3c1157d,
title = "Subcellular localization of the camptothecin analogues, topotecan and gimatecan",
abstract = "Lipophilicity of camptothecins derivatives has been reported to improve the stability of the lactone ring and to favor rapid uptake and intracellular accumulation. Recently, a novel series of lipophilic camptothecins substituted at position 7 was developed, and gimatecan (ST1481) was selected for clinical development on the basis of some favorable features, including potent cytotoxicity and the unique feature of the lack of recognition by breast cancer resistance-associated protein (BCRP). In this work the intrinsic fluorescence properties of this compound were exploited to investigate its intracellular disposition in comparison with the water-soluble camptothecin, topotecan (TPT), in HT-29 colon carcinoma cells and in a subline, HT-29/Mit, selected for resistance to mitoxantrone and overexpressing BCRP. The study was performed at single-cell level by means of microspectrofluorometry and fluorescence image analysis. The results indicated a quite different subcellular localization of TPT ST1481, since TPT localized mainly in mitochondria, whereas gimatecan exhibited a lysosomal localization. An increased persistence of DNA damage in gimatecan-treated cells was consistent with the interpretation that lysosomes represent a store of active drug. In contrast to gimatecan, which showed a similar localization in HT-29 cells and in the mitoxantrone-resistant subline, the cellular pharmacokinetic of TPT was markedly influenced by overexpression of BCRP protein in the resistant subline. In conclusion, the present results indicating a quite different behavior of the two camptothecins suggest that, apart from intracellular accumulation, subcellular distribution plays a role in their cytotoxic potency and contributes to their pharmacological features.",
keywords = "A.u., Arbitrary units, BCRP, Breast cancer resistance-associate protein, Camptothecins, Colon carcinoma cells, F.I., Fluorescence intensity, Resistance, Subcellular localization, Topotecan, TPT",
author = "Croce, {Anna Cleta} and Giovanni Bottiroli and Rosanna Supino and Enrica Favini and Valentina Zuco and Franco Zunino",
year = "2004",
month = "3",
day = "15",
doi = "10.1016/j.bcp.2003.10.034",
language = "English",
volume = "67",
pages = "1035--1045",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Subcellular localization of the camptothecin analogues, topotecan and gimatecan

AU - Croce, Anna Cleta

AU - Bottiroli, Giovanni

AU - Supino, Rosanna

AU - Favini, Enrica

AU - Zuco, Valentina

AU - Zunino, Franco

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Lipophilicity of camptothecins derivatives has been reported to improve the stability of the lactone ring and to favor rapid uptake and intracellular accumulation. Recently, a novel series of lipophilic camptothecins substituted at position 7 was developed, and gimatecan (ST1481) was selected for clinical development on the basis of some favorable features, including potent cytotoxicity and the unique feature of the lack of recognition by breast cancer resistance-associated protein (BCRP). In this work the intrinsic fluorescence properties of this compound were exploited to investigate its intracellular disposition in comparison with the water-soluble camptothecin, topotecan (TPT), in HT-29 colon carcinoma cells and in a subline, HT-29/Mit, selected for resistance to mitoxantrone and overexpressing BCRP. The study was performed at single-cell level by means of microspectrofluorometry and fluorescence image analysis. The results indicated a quite different subcellular localization of TPT ST1481, since TPT localized mainly in mitochondria, whereas gimatecan exhibited a lysosomal localization. An increased persistence of DNA damage in gimatecan-treated cells was consistent with the interpretation that lysosomes represent a store of active drug. In contrast to gimatecan, which showed a similar localization in HT-29 cells and in the mitoxantrone-resistant subline, the cellular pharmacokinetic of TPT was markedly influenced by overexpression of BCRP protein in the resistant subline. In conclusion, the present results indicating a quite different behavior of the two camptothecins suggest that, apart from intracellular accumulation, subcellular distribution plays a role in their cytotoxic potency and contributes to their pharmacological features.

AB - Lipophilicity of camptothecins derivatives has been reported to improve the stability of the lactone ring and to favor rapid uptake and intracellular accumulation. Recently, a novel series of lipophilic camptothecins substituted at position 7 was developed, and gimatecan (ST1481) was selected for clinical development on the basis of some favorable features, including potent cytotoxicity and the unique feature of the lack of recognition by breast cancer resistance-associated protein (BCRP). In this work the intrinsic fluorescence properties of this compound were exploited to investigate its intracellular disposition in comparison with the water-soluble camptothecin, topotecan (TPT), in HT-29 colon carcinoma cells and in a subline, HT-29/Mit, selected for resistance to mitoxantrone and overexpressing BCRP. The study was performed at single-cell level by means of microspectrofluorometry and fluorescence image analysis. The results indicated a quite different subcellular localization of TPT ST1481, since TPT localized mainly in mitochondria, whereas gimatecan exhibited a lysosomal localization. An increased persistence of DNA damage in gimatecan-treated cells was consistent with the interpretation that lysosomes represent a store of active drug. In contrast to gimatecan, which showed a similar localization in HT-29 cells and in the mitoxantrone-resistant subline, the cellular pharmacokinetic of TPT was markedly influenced by overexpression of BCRP protein in the resistant subline. In conclusion, the present results indicating a quite different behavior of the two camptothecins suggest that, apart from intracellular accumulation, subcellular distribution plays a role in their cytotoxic potency and contributes to their pharmacological features.

KW - A.u.

KW - Arbitrary units

KW - BCRP

KW - Breast cancer resistance-associate protein

KW - Camptothecins

KW - Colon carcinoma cells

KW - F.I.

KW - Fluorescence intensity

KW - Resistance

KW - Subcellular localization

KW - Topotecan

KW - TPT

UR - http://www.scopus.com/inward/record.url?scp=1542330612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542330612&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2003.10.034

DO - 10.1016/j.bcp.2003.10.034

M3 - Article

C2 - 15006540

AN - SCOPUS:1542330612

VL - 67

SP - 1035

EP - 1045

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 6

ER -